This study is testing two courses of strong chemotherapy, Thiotepa, Cyclophosphamide, Melphalan, Etoposide, and Carboplatin, followed by a stem cell rescue, for patients with high-risk neuroblastoma. This treatment is given after initial chemotherapy. The study aims to see how long patients live without their cancer getting worse (Progression Free Survival) for three years after their first stem cell transplant. You may be able to join if you are under 30 years old at diagnosis, have completed initial chemotherapy, and meet certain health requirements. This study is currently unclear on its recruitment status and plans to enroll 12 participants.

Study design

This is a Phase II single-center study that will enroll 12 participants.

What's involved

You would receive two courses of strong chemotherapy, each followed by a stem cell rescue. Ideally, this treatment should start within 4-8 weeks after your fifth cycle of induction chemotherapy.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for Progression Free Survival for three years after your first stem cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.